The Republic of Iceland – Government Debt Management
Today the Republic of Iceland issued a bond in the amount of 750 million euros, the equivalent of ISK 117bn. The bond bears fixed 0% interest and is issued for seven years at a yield of 0,117%.
Investors showed keen interest, with demand totalling EUR 3.5bn, or more than four times the amount of the issue. The investor group comprises banks, insurance companies, and other institutional investors, mainly from Northern Europe. Joint lead managers for the issue were Citibank, Barclays, and Deutsche Bank.
"The investor response is a sign that the Treasury has ready access to global markets. It reflects confidence in our strength and our ability to address the economic repercussions of the global pandemic. With this bond issue, the Treasury further strengthens its long-term situation, as its liquidity position is very good at present," said Minister of Finance and Economic Affairs Bjarni Benediktsson.
During the book building process, the Treasury’s terms improved by 12 basis points from the initial price guidance. The buyer group included well over 150 investors.
"Today’s issue is in line with the Treasury’s debt management strategy, as the Government’s increased financing needs in coming years will partly be met with foreign borrowing or by tapping the Treasury’s foreign-denominated deposits with the Central Bank of Iceland. Market conditions are particularly favourable at present, as the terms on today’s issue demonstrate," said the Minister.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Genmab A/S18.10.2025 12:00:34 CEST | Press release
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
F. Hoffmann-La Roche Ltd18.10.2025 07:00:00 CEST | Press release
Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer
StoneX Group Inc.18.10.2025 01:12:36 CEST | Press release
StoneX Expands Wealth Management Offering for Latin American Clients
F. Hoffmann-La Roche Ltd17.10.2025 22:20:00 CEST | Press release
Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
Eavor Technologies Inc.17.10.2025 18:00:00 CEST | Press release
Mark Fitzgerald Appointed President and Chief Executive Officer of Eavor Technologies Inc.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom